Latest News on KRRO

Financial News Based On Company


Advertisement
Advertisement

Three conference appearances take Korro Bio’s CEO to Miami and New York from Dec. 1–3.

https://www.stocktitan.net/news/KRRO/korro-to-participate-in-upcoming-investor-hgf7faoczqst.html
Korro Bio (Nasdaq: KRRO) announced that CEO and President Ram Aiyar will participate in three investor conferences in December 2026. He will engage in fireside chats and one-on-one meetings at the 9th Annual Evercore Healthcare Conference, Citi’s 2026 Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference. The conferences are scheduled from December 1-3, 2026, in Miami and New York.

Seven holders report the same Korro Bio (KRRO) stake, with warrant exercises capped.

https://www.stocktitan.net/sec-filings/KRRO/schedule-13g-a-korro-bio-inc-amended-passive-investment-disclosure-4af1e6e5ef10.html
A Schedule 13G/A filing indicates that a Venrock group, comprising seven reporting persons, collectively holds a 9.99% beneficial ownership stake in Korro Bio (KRRO), amounting to 1,474,162 shares as of September 30, 2026. This ownership includes common shares and pre-funded warrants, with a beneficial ownership blocker preventing exercise if it would exceed the 9.99% threshold. The filing also details the breakdown of holdings across different Venrock entities and identifies Nimish Shah and Bong Y. Koh as voting members of the management entities.

Two Atlas funds hold 869,331 shares behind a reported passive stake in Korro Bio (KRRO).

https://www.stocktitan.net/sec-filings/KRRO/schedule-13g-a-korro-bio-inc-amended-passive-investment-disclosure-0eed03bb4d6e.html
Balyasny Asset Management L.P. and affiliated entities have reported a passive stake of approximately 5.9% in Korro Bio, Inc. (KRRO), totaling 869,331 common shares. These shares are held directly by Atlas Diversified Master Fund, Ltd. and Atlas Private Holdings (Cayman) Ltd., both clients of Balyasny Asset Management. The filing indicates that each of the five reporting persons, including Dmitry Balyasny, may be deemed beneficial owners of this position.

Six planned share sales at Korro Bio (KRRO) span November 11–12, 2026.

https://www.stocktitan.net/sec-filings/KRRO/form-4-korro-bio-inc-insider-trading-activity-77ab5d9ae760.html
Korro Bio director Jean Francois Formela reported the sale of 66,632 shares of KRRO, held indirectly through Atlas Venture funds, across six transactions on November 11 and 12, 2026. These sales were executed under a Rule 10b5-1 trading plan established on April 8, 2026, with weighted-average prices ranging from $14.30 to $15.60 per share. Following these transactions, the indirect holdings amount to 121,219 shares.

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

https://www.manilatimes.net/2026/11/14/tmt-newswire/globenewswire/korro-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635c4/2469861
Korro Bio, Inc. announced the grant of a non-statutory stock option to a newly hired employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant allows the employee to purchase 1,000 shares of common stock at $14.41 per share, vesting over four years. Korro Bio is a clinical-stage biopharmaceutical company focused on developing genetic medicines for rare and prevalent diseases using its OPERA® platform.
Advertisement

Form 144 Korro Bio For: 13 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-korro-bio-for-13-november-93CH-4955552
This article is a brief announcement from Investing.com regarding a Form 144 filing for Korro Bio on November 13. The content is primarily a placeholder, indicating the date of the filing and its publication on Investing.com.

11,431 Korro Bio (KRRO) shares are proposed for sale by Atlas Venture Opportunity Fund II.

https://www.stocktitan.net/sec-filings/KRRO/144-korro-bio-inc-sec-filing-5f414a168d96.html
Atlas Venture Opportunity Fund II, L.P., a shareholder of Korro Bio, Inc. (KRRO), has filed a Form 144 to propose the sale of 11,431 common shares valued at $164,720.71, with an approximate sale date of November 12, 2026. These shares were acquired in a private placement on April 22, 2024. The filing also details prior sales by Atlas Venture Opportunity Fund II and Atlas Venture Fund XI, L.P. between August 19 and November 11, 2026, and notes an April 8, 2026, plan adoption date under Rule 10b5-1.

A 1 million-share passive stake in Korro Bio (KRRO) links a fund manager and two managing members.

https://www.stocktitan.net/sec-filings/KRRO/schedule-13g-korro-bio-inc-passive-investment-disclosure-5-65953dbccd56.html
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a 6.79% passive stake in Korro Bio, Inc. (KRRO), each beneficially owning 1,000,000 shares. This disclosure, filed on Schedule 13G, indicates shared voting and dispositive power over these shares, which are directly held by Adage Capital Partners, L.P. The stake is calculated based on 14,725,646 shares outstanding as of August 5, 2026.

Adage Capital Management Reveals 6.79% Stake in Korro Bio Inc.

https://kalkinemedia.com/us/news/announcements/adage-capital-management-reveals-679-stake-in-korro-bio-inc
Adage Capital Management, along with Robert Atchinson and Phillip Gross, reported a beneficial ownership of 1,000,000 shares of Korro Bio, Inc. common stock, representing 6.79% of the outstanding shares. This stake was disclosed in a Schedule 13G filing with the SEC on November 12, 2026, stemming from an event on September 30, 2026. The filing indicates shared voting and dispositive powers and states the acquisition was made in the ordinary course of business without intent to influence control of the issuer.

Novo Terminates Research Collaboration With Korro Bio

https://www.pharmexec.com/view/novo-terminates-research-collaboration-korro-bio
Novo has terminated its research collaboration and license agreement with Korro Bio, effective February 1, 2027. The partnership, which focused on cardiometabolic RNA-editing, was paused for 12 months, during which Korro earned no milestone payments. This termination shifts Korro Bio's focus to its wholly controlled rare-disease programs amidst a challenging biotech funding environment.
Advertisement

Korro to Present at the 2026 Jefferies Global Healthcare Conference in London

https://www.manilatimes.net/2026/11/06/tmt-newswire/globenewswire/korro-to-present-at-the-2026-jefferies-global-healthcare-conference-in-london/2464002
Korro Bio, Inc. (Nasdaq: KRRO), a clinical-stage biopharmaceutical company, announced that its CEO and President, Ram Aiyar, Ph.D., will present at the 2026 Jefferies Global Healthcare Conference in London. The presentation, focusing on their novel OPERA® platform for genetic medicines, is scheduled for Thursday, November 19th, at 8:00 AM GMT. A live webcast and subsequent replay will be available on Korro’s investor relations website.

Korro Bio CEO to present at 2026 Jefferies Global Healthcare Conference in London

https://pluang.com/en/news-feed/korro-akan-mempresentasikan-di-konferensi-kesehatan-global-jefferies-2026
Korro Bio, a clinical-stage biopharmaceutical company, announced that CEO Ram Aiyar will present at the 2026 Jefferies Global Healthcare Conference in London on November 19. The company specializes in genetic medicines using its OPERA platform to develop RNA-editing treatments for various diseases. The presentation will be webcast live, providing insights into Korro's innovative approach and upcoming developments in RNA-editing therapies.

A medicine developer's CEO is set to present in London on Nov. 19

https://www.stocktitan.net/news/KRRO/korro-to-present-at-the-2026-jefferies-global-healthcare-conference-vu6gd5axmx1i.html
Korro Bio (Nasdaq: KRRO), a clinical-stage biopharmaceutical company, announced that its CEO and President, Ram Aiyar, Ph.D., will present at the 2026 Jefferies Global Healthcare Conference in London on November 19, 2026. The presentation will cover the company's novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform for developing genetic medicines. A live webcast and replay of the presentation will be available for investors.

Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update

https://www.manilatimes.net/2026/11/05/tmt-newswire/globenewswire/korro-reports-third-quarter-2026-financial-results-and-provides-corporate-update/2462827
Korro Bio, Inc. announced its Q3 2026 financial results, reporting $124.8 million in cash, cash equivalents, and marketable securities, extending its cash runway into the second half of 2028. The company provided a corporate update, including initiating dosing in the Phase 1/2 ANCHOR trial for KRRO-121 in Urea Cycle Disorders (UCDs) and achieving best-in-class preclinical data for KRRO-111 in Alpha-1 Antitrypsin Deficiency (AATD). Korro anticipates key milestones in 2027, such as dosing UCD participants with KRRO-121 and a regulatory submission for KRRO-111.

Korro Bio Reports Q3 2026 Results with 13.7M Shares Outstanding and Pipeline Updates

https://kalkinemedia.com/us/news/announcements/korro-bio-reports-q3-2026-results-with-137m-shares-outstanding-and-pipeline-updates
Korro Bio, Inc. submitted its Q3 2026 Form 10-Q report, detailing 13,725,646 shares outstanding as of November 3, 2026. The report highlighted progress in the ANCHOR Phase 1/2 clinical trial for KRRO-121, including completion of Part 1 in healthy volunteers and planned patient dosing, along with the preclinical status of KRRO-111. Additionally, Korro Bio announced the termination of its collaboration with Novo Nordisk, with deferred revenue expected to be recognized in Q4 2026.
Advertisement

Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update

https://www.stocktitan.net/news/KRRO/korro-reports-third-quarter-2026-financial-results-and-provides-zthfqwr6koo6.html
Korro Bio announced the start of dosing healthy volunteers with KRRO-121 in its Phase 1/2 ANCHOR trial and reported its Q3 2026 financial results. The company expects to dose urea cycle disorder participants in H1 2027 and release interim data in H2 2027. Preclinical data for KRRO-111 showed over 95% editing of SERPINA1 RNA transcripts in mice and approximately 95% elimination of pathogenic liver Z-AAT protein, with a regulatory application planned for H1 2027. Korro ended the quarter with $124.8 million in cash, projecting a runway into H2 2028.

Korro Bio, Inc. (KRRO) Seasonal returns chart

https://uk.finance.yahoo.com/quote/KRRO/seasonality/
The article provides a seasonal returns chart for Korro Bio, Inc. (KRRO), displaying the average monthly price return from 2019 to 2026. It includes current stock performance data, showing the stock price and recent percentage changes during regular and overnight trading sessions.

Korro Bio, Inc. (KRRO) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/KRRO/seasonality/
This article provides a seasonal returns chart for Korro Bio, Inc. (KRRO), displaying average monthly price returns from 2019 to 2026. It includes current stock information, showing KRRO's real-time price on NasdaqCM and its performance during regular market hours and overnight trading. The page also features an overview of various market indices and cryptocurrency prices.

Oppenheimer Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $22

https://www.moomoo.com/news/post/1002796787/oppenheimer-maintains-korro-bio-krrous-with-buy-rating-maintains-target
Oppenheimer has reiterated its Buy rating on Korro Bio (KRRO.US), maintaining a target price of $22. This indicates a continued positive outlook on the company's stock performance from the financial firm.

Korro Bio | SCHEDULE 13G/A: Others

https://www.moomoo.com/news/notice/1002548452/others
This document is a SCHEDULE 13G/A filing related to Korro Bio, indicating an amended statement of beneficial ownership by a reporting person or group. The filing category is "Others," suggesting it falls outside standard institutional or insider reporting.
Advertisement

BlackRock units amend their Korro Bio (KRRO) stake disclosure, excluding other business units.

https://www.stocktitan.net/sec-filings/KRRO/schedule-13g-a-korro-bio-inc-amended-passive-investment-disclosure-d7b632240540.html
BlackRock, Inc. has filed an amended Schedule 13G/A for Korro Bio, Inc. (KRRO), reporting that certain BlackRock business units beneficially own 717,813 common shares, representing a 4.9% stake as of September 30, 2026. The disclosure specifies that other BlackRock business units' ownership is disaggregated and excluded from this filing, with no single person's interest exceeding 5%. The reported units hold sole voting power over 699,169 shares and sole dispositive power over 717,813 shares.

Korro Bio: 10% owner Lynx1 Capital Management LP buys $884,751 stock

https://www.investing.com/news/insider-trading-news/korro-bio-10-owner-lynx1-capital-management-lp-buys-884751-stock-93CH-4973925
Lynx1 Capital Management LP, a 10% owner of Korro Bio, Inc. (NASDAQ:KRRO), recently purchased $884,751 worth of common stock over several days in late October 2026, increasing its stake in the biotechnology company. These acquisitions coincided with a 35% rally in KRRO shares, bringing the current stock price to $12.02. The company also announced progress in its Phase 1/2 clinical trial for KRRO-121, with H.C. Wainwright and Raymond James reiterating Buy and Outperform ratings respectively.

Across three dates, Lynx1 Master Fund buys 79,809 Korro Bio (KRRO) shares.

https://www.stocktitan.net/sec-filings/KRRO/form-4-korro-bio-inc-insider-trading-activity-63cbe97e177f.html
Lynx1 Master Fund LP reported the purchase of 79,809 shares of Korro Bio (KRRO) across four transactions on October 22, 23, and 26, 2026. The weighted-average purchase prices ranged from $9.6764 to $12.1061 per share. Lynx1 Capital Management LP and Weston Nichols, identified as ten-percent owners, disclaim beneficial ownership except for their pecuniary interest.

Korro Bio, Inc. Estimates – NASDAQ:KRRO

https://www.tradingview.com/symbols/NASDAQ-KRRO/financials-estimates/
This article provides an overview of Korro Bio, Inc. (NASDAQ: KRRO) financial estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, allowing comparison of actual results with average, high, and low estimates, and visualization of trends over time. The content emphasizes that this information is not investment advice and encourages users to conduct their own research.

H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15

https://www.moomoo.com/news/post/1002209739/hc-wainwright-maintains-korro-bio-krrous-with-buy-rating-maintains
H.C. Wainwright has reiterated its Buy rating for Korro Bio (KRRO.US) and maintained a target price of $15. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Advertisement

Korro Bio reports preclinical data for AATD treatment KRRO-111

https://www.investing.com/news/company-news/korro-bio-reports-preclinical-data-for-aatd-treatment-krro111-93CH-4965475
Korro Bio Inc. announced positive preclinical results for KRRO-111, an investigational treatment for alpha-1 antitrypsin deficiency (AATD). Studies in mice showed significant SERPINA1 mRNA editing, increased total AAT, and reduced pathogenic Z-AAT. The company plans to submit a regulatory filing for KRRO-111 in the first half of 2027.

Korro Bio | 8-K: Current report

https://www.moomoo.com/news/notice/1002013564/current-report
This document is a current report filed by Korro Bio on Form 8-K. The 8-K form is used to announce material events or corporate changes that shareholders should know about. No specific details of the event are provided in this truncated content.

Form 8K Korro Bio Inc For: 22 October By Investing.com

https://ng.investing.com/news/stock-market-news/form-8k-korro-bio-inc-for-22-october-93CH-2750897
This article reports on Korro Bio Inc.'s Form 8K filing for October 22nd. Form 8K is a crucial document that public companies must file with the SEC to announce major events that shareholders should know about. The brief announcement by Investing.com highlights this financial disclosure.

Korro Bio Announces Preclinical Results for KRRO-111 Targeting Alpha-1 Antitrypsin Deficiency

https://kalkinemedia.com/us/news/announcements/korro-bio-announces-preclinical-results-for-krro-111-targeting-alpha-1-antitrypsin-deficiency
Korro Bio, Inc. (NASDAQ:KRRO) has announced preclinical results for KRRO-111, its development candidate for Alpha-1 Antitrypsin Deficiency. The company filed a Form 8-K on October 22, 2026, detailing these findings, with the full press release included as Exhibit 99.1. Ram Aiyar, President, CEO, and Interim CFO, signed the filing for the Delaware corporation.

Form 8K Korro Bio Inc For: 22 October By Investing.com

https://au.investing.com/news/stock-market-news/form-8k-korro-bio-inc-for-22-october-93CH-4707377
This article announces that Korro Bio Inc. has filed a Form 8K on October 22, 2026. The filing is available through Investing.com, a financial markets platform. No specific details about the content of the 8K filing are provided within the article text.
Advertisement

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency

https://finance.yahoo.com/healthcare/articles/korro-reports-best-class-preclinical-110000493.html
Korro Bio announced positive preclinical results for KRRO-111, an RNA editing therapy for Alpha-1 Antitrypsin Deficiency (AATD). Studies showed KRRO-111 restored functional M-AAT and significantly reduced toxic Z-AAT in the liver, suggesting it can address both lung and liver manifestations of the disease. The company expects to submit for regulatory approval in the first half of 2027.

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://finance.yahoo.com/healthcare/articles/korro-bio-reports-inducement-grants-200500094.html
Korro Bio, Inc. announced the grant of non-statutory stock options to two new employees as an inducement for their employment. These options cover 4,000 shares of common stock at an exercise price of $8.88 per share, vesting over four years. The grants were approved by Korro's Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4).

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.manilatimes.net/2026/10/17/tmt-newswire/globenewswire/korro-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2447758
Korro Bio announced the grant of non-statutory stock options to two new employees as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These options allow the employees to purchase a total of 4,000 shares of Korro's common stock at an exercise price of $8.88 per share, vesting over four years. This move aligns with Korro's strategy to attract talent to further its work in developing genetic medicines using its OPERA® platform.

Korro Bio grants 4,000 inducement options to two hires | KRRO Stock News

https://www.stocktitan.net/news/KRRO/korro-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-7geekxa14xh7.html
Korro Bio (KRRO) has granted 4,000 non-statutory stock options to two new employees as an inducement to employment, effective October 14, 2026. These options have an exercise price of $8.88 per share, matching the Nasdaq closing price on the grant date, and vest over four years subject to continued service. The grants were approved by the independent Compensation Committee under Korro's 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.wboc.com/online_features/press_releases/korro-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4/article_f3f411e4-71c2-590b-a68b-0a438d13200a.html
Korro Bio, Inc. announced the grant of non-statutory stock options to two new employees as an inducement to employment. These grants, totaling 4,000 shares at an exercise price of $8.88 per share, were approved by the company's Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, subject to continued employment.
Advertisement

Oppenheimer Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $22

https://www.moomoo.com/news/post/1000664434/oppenheimer-maintains-korro-bio-krrous-with-buy-rating-maintains-target
Oppenheimer has reiterated its Buy rating for Korro Bio (KRRO.US) and maintained its price target of $22. This indicates a continued positive outlook from the firm regarding the company's stock performance.

H.C. Wainwright reiterates Korro Bio stock rating on trial dosing By Investing.com

https://ng.investing.com/news/stock-market-news/hc-wainwright-reiterates-korro-bio-stock-rating-on-trial-dosing-93CH-2723436
H.C. Wainwright has reiterated its Buy rating and $15.00 price target for Korro Bio Inc. (NASDAQ:KRRO) after the company announced the dosing of the first cohort in its Phase 1/2 clinical trial for KRRO-121. Despite a significant stock decline over the past year, InvestingPro analysis suggests the biotech firm is undervalued and financially stable, with substantial cash reserves. KRRO-121 is being developed for hyperammonemia, and the global ANCHOR trial is currently enrolling healthy volunteers in Australia, with primary completion estimated in the second half of 2027.

H.C. Wainwright reiterates Korro Bio stock rating on trial dosing By Investing.com

https://au.investing.com/news/stock-market-news/hc-wainwright-reiterates-korro-bio-stock-rating-on-trial-dosing-93CH-4674982
H.C. Wainwright has reiterated a Buy rating and a $15.00 price target for Korro Bio Inc. (NASDAQ:KRRO) after the company announced the dosing of the first cohort in its Phase 1/2 clinical trial for KRRO-121. The drug is being developed to treat hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. Despite a significant drop in stock price over the past year, InvestingPro analysis suggests the company may be undervalued, supported by a strong financial position to fund its clinical trials.

H.C. Wainwright reiterates Korro Bio stock rating on trial dosing By Investing.com

https://in.investing.com/news/stock-market-news/hc-wainwright-reiterates-korro-bio-stock-rating-on-trial-dosing-93CH-5620256
H.C. Wainwright has reiterated a Buy rating and a $15.00 price target for Korro Bio Inc. (NASDAQ:KRRO) after the company announced it had dosed the first cohort of participants in its Phase 1/2 clinical trial for KRRO-121. Despite a 77% drop in stock price over the past year, InvestingPro analysis suggests the company may be undervalued, boasting a strong current ratio and more cash than debt. KRRO-121 is being developed for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, with the global ANCHOR trial expected to complete its primary phase in the second half of 2027.

HC Wainwright & Co. reiterates Buy rating on Korro Bio, $15 price target

https://www.tradingview.com/news/tradingview:8495a610476e7:0-hc-wainwright-co-reiterates-buy-rating-on-korro-bio-15-price-target/
HC Wainwright & Co. has reiterated its Buy rating for Korro Bio (KRRO) with a $15 price target, representing a 50.5% upside. This positive outlook is driven by the initiation of a Phase 1/2 clinical trial for KRRO-121, targeting hyperammonemia in urea cycle disorders, and the well-defined regulatory pathway for this treatment.
Advertisement

Korro Bio doses first patients in urea cycle disorder trial By Investing.com

https://ng.investing.com/news/stock-market-news/korro-bio-doses-first-patients-in-urea-cycle-disorder-trial-93CH-2722369
Korro Bio Inc. (NASDAQ:KRRO) has begun its Phase 1/2 clinical trial for KRRO-121, a treatment for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, by administering the first doses to healthy volunteers in Australia. The trial, named ANCHOR, will proceed with dosing urea cycle disorder patients in the first half of 2027 and aims to assess the treatment's ability to reduce ammonia accumulation. KRRO-121 is an RNA-editing oligonucleotide designed to enhance glutamine synthetase protein production for ammonia clearance.

Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121

https://www.manilatimes.net/2026/10/06/tmt-newswire/globenewswire/korro-announces-first-cohort-dosed-in-phase-12-clinical-trial-anchor-for-krro-121/2439441/amp
Korro Bio, a clinical-stage biopharmaceutical company, announced that the first cohort of participants has been dosed in its Phase 1/2 clinical trial (ANCHOR) for KRRO-121. This drug is designed to treat hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of KRRO-121 in healthy volunteers, with dosing in UCD patients expected to begin in the first half of 2027.

Korro Bio doses first patients in urea cycle disorder trial

https://www.investing.com/news/company-news/korro-bio-doses-first-patients-in-urea-cycle-disorder-trial-93CH-4932835
Korro Bio Inc. has initiated its Phase 1/2 clinical trial for KRRO-121, a treatment candidate for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, by administering the first doses to healthy volunteers in Australia. The ANCHOR trial will progress from a Phase 1 study in healthy participants to a Phase 2 study in urea cycle disorder patients, with an interim readout expected in the second half of 2027. KRRO-121 is an RNA-editing oligonucleotide designed to enhance ammonia clearance, addressing the dangerous accumulation of ammonia associated with these rare metabolic conditions.

Korro Bio, Inc. (KRRO) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/KRRO/
Korro Bio, Inc. (KRRO) is a biopharmaceutical company focused on developing genetic medicines based on RNA editing for various diseases. The company's stock is currently trading at $9.41, down 2.39%, with a 1-year target estimate of $20.20. Key financial data, performance overview, earnings trends, and analyst insights for KRRO are also presented.

Korro Bio Inc (KRRO-Q) Stock Price and News

https://www.theglobeandmail.com/investing/markets/stocks/KRRO/
This article provides stock information and recent news for Korro Bio Inc. (KRRO-Q), an RNA editing company. It highlights recent analyst ratings, including several "Buy" ratings from Tipranks, and news about their first human clinical trial and selection of a development candidate for Alpha-1 Antitrypsin Deficiency. The company's profile as a developer of precision genetic medicines is also included.
Advertisement

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

https://www.moomoo.com/news/post/76162802/korro-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635
Korro Bio has reported an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant involves options to purchase 45,000 shares of common stock, vesting over four years. This grant was approved by the company's Board of Directors and is a material inducement for the employee to join Korro Bio.

Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely?

https://www.moomoo.com/news/post/76485515/will-korro-bio-nasdaq-krro-spend-its-cash-wisely
This article examines whether Korro Bio (NASDAQ:KRRO) has sufficient cash to fund its operations for at least 12 months. It analyzes the company's cash burn rate against its cash reserves and highlights factors like shareholder dilution and future capital needs. The piece concludes by suggesting that while Korro Bio appears to have adequate cash for now, potential investors should monitor its cash flow trends.

Formela Jean Francois Sells 48,690 Korro Bio Shares, Retains 132,650 Shares Post-Transaction

https://kalkinemedia.com/us/news/announcements/formela-jean-francois-sells-48690-korro-bio-shares-retains-132650-shares-post-transaction
Formela Jean Francois sold 48,690 shares of Korro Bio (NASDAQ:KRRO) in four open-market transactions between September 11 and September 14, 2026, with prices ranging from $13.99 to $14.12 per share. Following these sales, her total holdings in the company are now 132,650 shares. The transactions were recorded under SEC code S, indicating open-market or private sales.

Korro Bio (KRRO) finance SVP’s 5-share sale comes under a preset trading plan

https://www.stocktitan.net/sec-filings/KRRO/form-4-korro-bio-inc-insider-trading-activity-052f79df83aa.html
Korro Bio's Senior Vice President of Finance, Oliver Dolan, sold 5 shares of common stock at a weighted-average price of $13.716 per share on September 11, 2026. This transaction was executed under a Rule 10b5-1 trading plan established on June 8, 2026. Following the sale, Dolan retains 16,241 shares, all of which are unvested RSUs scheduled to vest between December 2026 and July 2028.

Nearly 49,000 Korro Bio (KRRO) shares sold by director-linked funds

https://www.stocktitan.net/sec-filings/KRRO/form-4-korro-bio-inc-insider-trading-activity-24aeeb1cfd52.html
Korro Bio director Jean Francois Formela's affiliated funds, Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P., sold a total of 48,690 shares of KRRO common stock. These sales occurred on September 11 and September 14, 2026, at weighted average prices around $14 per share, executed under a Rule 10b5-1 trading plan. Formela disclaims Section 16 beneficial ownership except for any pecuniary interest.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement